Music Therapy for Prematurity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the benefits of music therapy for newborns born prematurely. Babies will either hear soothing sounds from an ocean disc or experience silence, both in a random order over two weeks. Researchers aim to determine if these sounds can improve breathing, heart rate, and oxygen levels. Babies born between 24 and 37 weeks at Mount Sinai Hospital who are suitable for music therapy may be eligible. The trial seeks to discover if music can provide comfort and improve health in premature infants. As an unphased trial, this study offers families a unique opportunity to contribute to groundbreaking research that could enhance the well-being of premature infants.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that this music therapy is safe for premature infants?
Research has shown that music therapy is generally safe for premature babies. Studies have found that it can improve their breathing and reduce anxiety in mothers. One study demonstrated that music therapy sessions created a calming environment for both babies and their families. Other research found that listening to music positively affected babies' heart rates and oxygen levels.
In neonatal care, caregivers carefully control the volume of music to prevent overstimulation and protect the babies' hearing. Overall, infants tolerate music therapy well, and current research indicates it does not pose significant safety concerns.12345Why are researchers excited about this trial?
Researchers are excited about music therapy for prematurity because it offers a non-invasive, calming intervention that can be used alongside traditional medical care. Unlike standard treatments for premature infants, which often focus on medical and nutritional support, music therapy aims to enhance neurological development through auditory stimulation. The use of an ocean disc for music therapy entrainment is believed to mimic the soothing sounds of the womb, potentially reducing stress and promoting better sleep patterns in premature babies. This innovative approach could improve long-term developmental outcomes without the side effects associated with pharmacological treatments.
What evidence suggests that music therapy might be an effective treatment for prematurity?
Research has shown that music therapy benefits premature babies. In this trial, participants in the intervention group will receive the ocean disc music therapy entrainment intervention. Studies have found that music therapy can improve breathing and sleep in premature infants. One study revealed that babies who received music therapy had better thinking, language, and movement skills by age two. Music therapy also creates a comforting environment for both the babies and their families in the NICU. Overall, early evidence suggests that music therapy could positively impact the development and well-being of premature infants.12467
Who Is on the Research Team?
Joanne V Loewy, DA, MT-BC, LCAT
Principal Investigator
Icahn School of Medicine at Mount Sinai
Are You a Good Fit for This Trial?
This trial is for preterm infants born at 24-37 weeks' gestation, considered appropriate for music therapy, and without genetic disorders or hearing issues. It's not suitable for extremely fragile infants unlikely to survive 24 hours or those of uncertain viability.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive six intervention days over a two-week period, with 3 sessions per week, involving ocean disc music therapy and control conditions
Follow-up
Participants are monitored for safety and effectiveness after treatment, including cerebral oxygen saturation measurements
What Are the Treatments Tested in This Trial?
Interventions
- Music Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor